Connect Biopharma Holdings Ltd
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
TABLE OF CONTENTS
FORM 10-Q FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
| PART I. | FINANCIAL INFORMATION | Page |
|---|---|---|
| ITEM 1. · Condensed Consolidated Financial Statements (unaudited) | ||
| Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (unaudited) | 4 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) | 5 | |
| Condensed Consolidated Statements of Shareholders’ Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) | 6 | |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) | 8 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 9 | |
| ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 |
| ITEM 3. | Quantitative and Qualitative Disclosures About Market Risk | 26 |
| ITEM 4. | Controls and Procedures | 26 |
| PART II. · OTHER INFORMATION | ||
| ITEM 1. | Legal Proceedings | 26 |
| ITEM 1A. | Risk Factors | 26 |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 28 |
| ITEM 3. | Defaults Upon Senior Securities | 28 |
| ITEM 4. | Mine Safety Disclosures | 28 |
| ITEM 5. | Other Information | 28 |
| ITEM 6. | Exhibits | 29 |
| SIGNATURES | 30 | |
EXPLANATORY NOTE
Connect Biopharma Holdings Limited (the “Company”), an exempted company incorporated under the laws of the Cayman Islands, qualifies as a “foreign private issuer,” as defined in Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) in the United States (the “U.S.”). The Company has voluntarily elected to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the U.S. Securities and Exchange Commission instead of filing on the reporting forms available to foreign private issuers.
Although the Company has voluntarily elected to file annual, periodic and current reports on U.S. domestic issuer forms, the Company intends to maintain its status as a foreign private issuer. Accordingly, as a foreign private issuer, the Company remains exempt from the U.S. federal proxy rules pursuant to Section 14 of the Exchange Act and Regulations 14A and 14C thereunder, Regulation FD, and its officers, directors, and principal shareholders are not subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.